about
Can administrative data be used to measure chemotherapy side effects?The magnitude and characteristics of the population of cancer survivors: using population-based estimates of cancer prevalence to inform service planning for survivorship careProjecting productivity losses for cancer-related mortality 2011 - 2030.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.The cost of premature cancer-related mortality: a review and assessment of the evidence.Productivity Losses Associated with Head and Neck Cancer Using the Human Capital and Friction Cost Approaches.Urban-rural differences in cancer-directed surgery and survival of patients with non-small cell lung cancer.Socioeconomic disadvantage but not remoteness affects short-term survival in prostate cancer: A population-based study using competing risks.Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis.Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study.Distance from treating hospital and colorectal cancer survivors' quality of life: a gendered analysis.Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): A population-based comparison.Clinical anxiety disorders in the context of cancer: A scoping review of impact on resource use and healthcare costsFinancial toxicity is more than costs of care: the relationship between employment and financial toxicity in long-term cancer survivorsDelays in access to affordable medicines: putting policy into perspective - authors' responseHigh discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphyDelays in access to affordable medicines: putting policy into perspectiveProductivity losses associated with premature mortality due to cancer in Russia: A population-wide study covering 2001-2030Development and usability evaluation of an online self-management intervention for fear of cancer recurrence (iConquerFear)
P50
Q30877306-E5438BDB-F4CB-48BD-87FF-E0F480D90AC5Q34438908-DE63B6B5-68B1-4BC5-BF7F-41FF9EBC0562Q36166785-B2C21E82-CB49-4F89-934C-15632DF9355EQ38152967-7DB96E65-9A60-4101-84C3-DE9554405C79Q38205587-6A873102-7090-4D20-8AD1-A47780362B1DQ39037810-8477F4B0-5605-47C5-A314-489F6C139D80Q39134717-BFE65BB4-B147-4527-B664-0AD8E32E00ACQ39456340-BF924E16-FC19-4580-B7D8-838CACD6432CQ40657322-277AFCDE-16F3-4267-AC0C-E292103478C8Q42706819-C669EBD6-D8E1-4611-B664-9C882BFDC578Q45729328-CE9F4042-F03A-4D4F-B3EB-A1B4C3D090B0Q50420740-2D2D7602-3264-42C1-9FE7-8160B7A261E0Q57163516-982E1017-554D-406C-A057-3C30BADE144AQ57792116-8D27E708-38A0-452C-98DD-E99124E2F5CFQ86939267-D12ADE8E-209D-4B11-8E29-8852A4DA7597Q87122620-F406E6E4-23BF-4194-BDA8-C3DD391A026AQ87438132-A30259B6-6B4F-4C87-89AC-2E9FBABB0608Q91953722-7B897211-AC64-421E-9DA7-97F24496A4B1Q93100126-DBB0AC19-4493-417F-AC0E-8CAA84432CDA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alison Pearce
@ast
Alison Pearce
@en
Alison Pearce
@es
Alison Pearce
@nl
type
label
Alison Pearce
@ast
Alison Pearce
@en
Alison Pearce
@es
Alison Pearce
@nl
prefLabel
Alison Pearce
@ast
Alison Pearce
@en
Alison Pearce
@es
Alison Pearce
@nl
P106
P31
P496
0000-0002-5690-9542